Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Winnacunnet High School senior Joe LaBrecque was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disorder. LaBrecque is raising awareness about the disease and participating in ...

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Aside from Myasthenia Gravis, Telitacicept has been approved in China for the treatment of two other major indications, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...

As such, UCB’s recently-debuted, U.S.-based DTC rare-disease campaign Imagine Your Zillions supports its gMG treatment Zilbrysq. The effort is based on flipping the preconceived notions associated ...